{"transactions":[{"id":702382,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":28337,"kind":"person","name":"FRENKEL JACOB A","position":1,"cik":"0001237418","reported_name":"FRENKEL JACOB A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-28T21:01:57.000Z","date":"2026-07-24","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock units (\"RSUs\") issued pursuant to a Consulting Agreement dated July 24, 2026 between the Reporting Person and the Issuer (the \"Consulting Agreement\") and subject to the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on October 24, 2026, and (ii) the remaining 50% of the award on April 24, 2027, provided that the Reporting Person continues to provide services to the Issuer pursuant to the Consulting Agreement through each applicable vesting date."}],"balance_after":343777,"source":{"system":"sec-edgar","filing":"0001104659-26-087588","document":"tm2621485-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926087588/tm2621485-2_4seq1.xml","form_type":"4"}},{"id":702381,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":28336,"kind":"person","name":"Pitts Peter Joe","position":1,"cik":"0002138486","reported_name":"Pitts Peter Joe","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-28T21:00:07.000Z","date":"2026-07-24","kind":"grant","planned":false,"acquired":true,"shares":900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest over 48 months, with 25% vesting on July 24, 2027 and 1/48th vesting monthly thereafter, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":900000,"derivative":{"exercise_price":1,"expiration_date":"2036-07-24","underlying":"Common Stock","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0001104659-26-087584","document":"tm2621485-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926087584/tm2621485-1_4seq1.xml","form_type":"4"}},{"id":759071,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-05-29T21:02:36.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":1800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock units (\"RSUs\") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":2000960,"source":{"system":"sec-edgar","filing":"0001104659-26-068339","document":"tm2615354-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926068339/tm2615354-5_4seq1.xml","form_type":"4"}},{"id":759070,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-05-29T21:02:01.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock units (\"RSUs\") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":218464,"source":{"system":"sec-edgar","filing":"0001104659-26-068338","document":"tm2615354-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926068338/tm2615354-4_4seq1.xml","form_type":"4"}},{"id":759068,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43250,"kind":"person","name":"Patlis Alla","position":1,"cik":"0001639227","reported_name":"Patlis Alla","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-29T21:01:34.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock units (\"RSUs\") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":144349,"source":{"system":"sec-edgar","filing":"0001104659-26-068337","document":"tm2615354-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926068337/tm2615354-3_4seq1.xml","form_type":"4"}},{"id":759069,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":28337,"kind":"person","name":"FRENKEL JACOB A","position":1,"cik":"0001237418","reported_name":"FRENKEL JACOB A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T21:01:00.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock units (\"RSUs\") awarded under the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":243777,"source":{"system":"sec-edgar","filing":"0001104659-26-068336","document":"tm2615354-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926068336/tm2615354-2_4seq1.xml","form_type":"4"}},{"id":759067,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43248,"kind":"person","name":"ARBEL IRIT","position":1,"cik":"0001245607","reported_name":"ARBEL IRIT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T21:00:26.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock units (\"RSUs\") awarded under the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":161054,"source":{"system":"sec-edgar","filing":"0001104659-26-068335","document":"tm2615354-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926068335/tm2615354-1_4seq1.xml","form_type":"4"}},{"id":770349,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":45751,"kind":"person","name":"Bairu Menghisteab","position":1,"cik":"0001891933","reported_name":"Bairu Menghisteab","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T22:07:24.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0.7,"value":105000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":150000,"derivative":{"exercise_price":0.7,"expiration_date":"2036-02-26","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001104659-26-064658","document":"tm267728-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926064658/tm267728-6_4seq1.xml","form_type":"4"}},{"id":770348,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":45750,"kind":"person","name":"Polverino Anthony J.","position":1,"cik":"0001729957","reported_name":"Polverino Anthony J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T22:06:21.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0.7,"value":105000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":150000,"derivative":{"exercise_price":0.7,"expiration_date":"2036-02-26","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001104659-26-064657","document":"tm267728-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926064657/tm267728-5_4seq1.xml","form_type":"4"}},{"id":770347,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":45749,"kind":"person","name":"HARTOUNIAN HARTOUN","position":1,"cik":"0001214476","reported_name":"HARTOUNIAN HARTOUN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T22:05:05.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0.7,"value":157500.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":225000,"derivative":{"exercise_price":0.7,"expiration_date":"2036-02-26","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001104659-26-064656","document":"tm267728-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926064656/tm267728-4_4seq1.xml","form_type":"4"}},{"id":770346,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":18220,"kind":"person","name":"Lindborg Stacy","position":1,"cik":"0001813667","reported_name":"Lindborg Stacy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T22:03:39.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0.7,"value":105000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":150000,"derivative":{"exercise_price":0.7,"expiration_date":"2036-02-26","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001104659-26-064653","document":"tm267728-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926064653/tm267728-3_4seq1.xml","form_type":"4"}},{"id":770345,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":28976,"kind":"person","name":"Naor Nir","position":1,"cik":"0001982278","reported_name":"Naor Nir","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T22:02:22.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0.7,"value":126000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":180000,"derivative":{"exercise_price":0.7,"expiration_date":"2036-02-26","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001104659-26-064652","document":"tm267728-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926064652/tm267728-2_4seq1.xml","form_type":"4"}},{"id":770344,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":45748,"kind":"person","name":"Dagher Ibrahim B.","position":1,"cik":"0002019599","reported_name":"Dagher Ibrahim B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T22:00:34.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0.7,"value":157500.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":225000,"derivative":{"exercise_price":0.7,"expiration_date":"2036-02-26","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001104659-26-064650","document":"tm267728-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926064650/tm267728-1_4seq1.xml","form_type":"4"}},{"id":1308493,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":45748,"kind":"person","name":"Dagher Ibrahim B.","position":1,"cik":"0002019599","reported_name":"Dagher Ibrahim B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-07T21:11:08.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":66849,"source":{"system":"sec-edgar","filing":"0001104659-25-001674","document":"tm251864-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925001674/tm251864-11_4seq1.xml","form_type":"4"}},{"id":1315842,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-01-03T22:36:42.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":200960,"source":{"system":"sec-edgar","filing":"0001104659-25-000895","document":"tm251864-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925000895/tm251864-10_4seq1.xml","form_type":"4"}},{"id":1315843,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":28337,"kind":"person","name":"FRENKEL JACOB A","position":1,"cik":"0001237418","reported_name":"FRENKEL JACOB A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-03T22:36:02.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock units (\"RSUs\") awarded under the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024."}],"balance_after":43777,"source":{"system":"sec-edgar","filing":"0001104659-25-000894","document":"tm251864-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925000894/tm251864-9_4seq1.xml","form_type":"4"}},{"id":1315841,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":45750,"kind":"person","name":"Polverino Anthony J.","position":1,"cik":"0001729957","reported_name":"Polverino Anthony J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-03T22:34:52.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock units (\"RSUs\") awarded under the 2014 Stock Incentive Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024."}],"balance_after":25730,"source":{"system":"sec-edgar","filing":"0001104659-25-000893","document":"tm251864-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925000893/tm251864-8_4seq1.xml","form_type":"4"}},{"id":1315840,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-01-03T22:34:08.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of restricted stock units (\"RSUs\") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024."}],"balance_after":68464,"source":{"system":"sec-edgar","filing":"0001104659-25-000892","document":"tm251864-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925000892/tm251864-7_4seq1.xml","form_type":"4"}},{"id":1315839,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-01-03T22:34:08.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan (the \"Plan\"). The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024."}],"balance_after":48464,"source":{"system":"sec-edgar","filing":"0001104659-25-000892","document":"tm251864-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925000892/tm251864-7_4seq1.xml","form_type":"4"}},{"id":1315838,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43250,"kind":"person","name":"Patlis Alla","position":1,"cik":"0001639227","reported_name":"Patlis Alla","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-01-03T22:33:21.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024."}],"balance_after":44349,"source":{"system":"sec-edgar","filing":"0001104659-25-000891","document":"tm251864-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925000891/tm251864-6_4seq1.xml","form_type":"4"}},{"id":1315837,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":28976,"kind":"person","name":"Naor Nir","position":1,"cik":"0001982278","reported_name":"Naor Nir","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-03T22:32:45.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":30666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock units (\"RSUs\") awarded under the 2014 Stock Incentive Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024."}],"balance_after":31465,"source":{"system":"sec-edgar","filing":"0001104659-25-000890","document":"tm251864-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925000890/tm251864-5_4seq1.xml","form_type":"4"}},{"id":1315836,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":18220,"kind":"person","name":"Lindborg Stacy","position":1,"cik":"0001813667","reported_name":"Lindborg Stacy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-03T22:32:08.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock units (\"RSUs\") awarded under the 2014 Stock Incentive Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024."}],"balance_after":48229,"source":{"system":"sec-edgar","filing":"0001104659-25-000889","document":"tm251864-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925000889/tm251864-4_4seq1.xml","form_type":"4"}},{"id":1315835,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":45749,"kind":"person","name":"HARTOUNIAN HARTOUN","position":1,"cik":"0001214476","reported_name":"HARTOUNIAN HARTOUN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-01-03T22:31:34.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024."}],"balance_after":52000,"source":{"system":"sec-edgar","filing":"0001104659-25-000888","document":"tm251864-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925000888/tm251864-3_4seq1.xml","form_type":"4"}},{"id":1315834,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":45751,"kind":"person","name":"Bairu Menghisteab","position":1,"cik":"0001891933","reported_name":"Bairu Menghisteab","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-03T22:31:00.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock units (\"RSUs\") awarded under the 2014 Stock Incentive Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":24000,"source":{"system":"sec-edgar","filing":"0001104659-25-000887","document":"tm251864-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925000887/tm251864-2_4seq1.xml","form_type":"4"}},{"id":1315833,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43248,"kind":"person","name":"ARBEL IRIT","position":1,"cik":"0001245607","reported_name":"ARBEL IRIT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-03T22:30:11.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":30666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock units (\"RSUs\") awarded under the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024."}],"balance_after":41054,"source":{"system":"sec-edgar","filing":"0001104659-25-000885","document":"tm251864-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925000885/tm251864-1_4seq1.xml","form_type":"4"}},{"id":1394961,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-10-02T12:00:14.000Z","date":"2024-10-01","kind":"purchase","planned":false,"acquired":true,"shares":1836,"price":3.4272,"value":6292.3392,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $3.40 to $3.45, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024."}],"balance_after":80960,"source":{"system":"sec-edgar","filing":"0001104659-24-105215","document":"tm2425378-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924105215/tm2425378-1_4seq1.xml","form_type":"4"}},{"id":1394960,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-10-02T12:00:14.000Z","date":"2024-09-30","kind":"purchase","planned":false,"acquired":true,"shares":22000,"price":0.228,"value":5016.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.2258 to $0.2302, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4."}],"balance_after":1186865,"source":{"system":"sec-edgar","filing":"0001104659-24-105215","document":"tm2425378-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924105215/tm2425378-1_4seq1.xml","form_type":"4"}},{"id":1445508,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-07-31T20:09:00.000Z","date":"2024-05-28","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":0.5183,"value":7774.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 3, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.5161 to $0.5194, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1164865,"source":{"system":"sec-edgar","filing":"0001104659-24-084344","document":"tm2420560-7_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924084344/tm2420560-7_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-06-03"}},{"id":1445507,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-07-31T20:08:32.000Z","date":"2024-05-22","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":0.64,"value":16000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 23, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'."}],"balance_after":1149865,"source":{"system":"sec-edgar","filing":"0001104659-24-084343","document":"tm2420560-6_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924084343/tm2420560-6_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-05-23"}},{"id":1445506,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-07-31T20:08:32.000Z","date":"2024-05-21","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":0.579,"value":14475.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 23, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'."}],"balance_after":1124865,"source":{"system":"sec-edgar","filing":"0001104659-24-084343","document":"tm2420560-6_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924084343/tm2420560-6_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-05-23"}},{"id":1445505,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-07-31T20:07:56.000Z","date":"2024-05-13","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.49,"value":4900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 14, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'."}],"balance_after":1099865,"source":{"system":"sec-edgar","filing":"0001104659-24-084341","document":"tm2420560-5_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924084341/tm2420560-5_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-05-14"}},{"id":1445504,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-07-31T20:07:56.000Z","date":"2024-05-11","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.4665,"value":4665.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 14, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'."}],"balance_after":1089865,"source":{"system":"sec-edgar","filing":"0001104659-24-084341","document":"tm2420560-5_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924084341/tm2420560-5_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-05-14"}},{"id":1445503,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-07-31T20:07:56.000Z","date":"2024-05-10","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.465,"value":9300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 14, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'."}],"balance_after":1079865,"source":{"system":"sec-edgar","filing":"0001104659-24-084341","document":"tm2420560-5_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924084341/tm2420560-5_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-05-14"}},{"id":1445502,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-07-31T20:07:31.000Z","date":"2024-05-07","kind":"purchase","planned":false,"acquired":true,"shares":66300,"price":0.3743,"value":24816.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 7, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.3738 to $0.3747, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1059865,"source":{"system":"sec-edgar","filing":"0001104659-24-084339","document":"tm2420560-4_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924084339/tm2420560-4_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-05-07"}},{"id":1445501,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-07-31T20:06:39.000Z","date":"2024-05-06","kind":"purchase","planned":false,"acquired":true,"shares":135000,"price":0.3753,"value":50665.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 7, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.3498 to $0.399, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":993565,"source":{"system":"sec-edgar","filing":"0001104659-24-084337","document":"tm2420560-3_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924084337/tm2420560-3_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-05-07"}},{"id":1445500,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-07-31T20:06:01.000Z","date":"2024-04-19","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":0.5199,"value":7798.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 25, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'."}],"balance_after":858565,"source":{"system":"sec-edgar","filing":"0001104659-24-084336","document":"tm2420560-2_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924084336/tm2420560-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-04-25"}},{"id":1445499,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-07-31T20:05:21.000Z","date":"2024-04-18","kind":"purchase","planned":false,"acquired":true,"shares":115072,"price":0.5255,"value":60470.336,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 19, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.4936 to $0.59, inclusive. The Reporting\nPerson undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of\nsecurities purchased at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":843565,"source":{"system":"sec-edgar","filing":"0001104659-24-084334","document":"tm2420560-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924084334/tm2420560-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-04-19"}},{"id":1445498,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-07-31T20:05:21.000Z","date":"2024-04-17","kind":"purchase","planned":false,"acquired":true,"shares":130000,"price":0.5457,"value":70941.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 19, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.5392 to $0.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":728493,"source":{"system":"sec-edgar","filing":"0001104659-24-084334","document":"tm2420560-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924084334/tm2420560-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-04-19"}},{"id":1449542,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":45748,"kind":"person","name":"Dagher Ibrahim B.","position":1,"cik":"0002019599","reported_name":"Dagher Ibrahim B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-07-24T20:05:18.000Z","date":"2024-07-19","kind":"sale","planned":false,"acquired":false,"shares":63000,"price":0.3503,"value":22068.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.3455 to $0.366, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-082328","document":"tm2420104-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924082328/tm2420104-1_4seq1.xml","form_type":"4"}},{"id":1469750,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":45749,"kind":"person","name":"HARTOUNIAN HARTOUN","position":1,"cik":"0001214476","reported_name":"HARTOUNIAN HARTOUN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-26T01:04:08.000Z","date":"2024-06-24","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option (the \"Option\"), awarded under the Plan, shall vest and become exercisable as to 25% of the underlying shares on June 24, 2025, and the remaining shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the grant date, provided that the Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date."}],"balance_after":60000,"derivative":{"exercise_price":0.38,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001104659-24-074873","document":"tm2418256-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924074873/tm2418256-2_4seq1.xml","form_type":"4"}},{"id":1469749,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":45749,"kind":"person","name":"HARTOUNIAN HARTOUN","position":1,"cik":"0001214476","reported_name":"HARTOUNIAN HARTOUN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-06-26T01:04:08.000Z","date":"2024-06-24","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock units (\"RSUs\") awarded under the Issuer's 2014 Stock Incentive Plan (the \"Plan\"). The RSUs will vest in full on June 24, 2025, provided that the Reporting Person remains employed by Issuer from the date of grant through the vesting date."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001104659-24-074873","document":"tm2418256-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924074873/tm2418256-2_4seq1.xml","form_type":"4"}},{"id":1495469,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-06-03T13:00:47.000Z","date":"2024-05-28","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0.5183,"value":7774.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.5161 to $0.5194, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":1164865,"source":{"system":"sec-edgar","filing":"0001104659-24-067529","document":"tm2416255-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924067529/tm2416255-1_4seq1.xml","form_type":"4"}},{"id":1504030,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-05-23T10:00:11.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0.64,"value":16000.0,"ownership":{"direct":true},"balance_after":1149865,"source":{"system":"sec-edgar","filing":"0001104659-24-064415","document":"tm2415334-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924064415/tm2415334-1_4seq1.xml","form_type":"4"}},{"id":1504029,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-05-23T10:00:11.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0.579,"value":14475.0,"ownership":{"direct":true},"balance_after":1124865,"source":{"system":"sec-edgar","filing":"0001104659-24-064415","document":"tm2415334-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924064415/tm2415334-1_4seq1.xml","form_type":"4"}},{"id":1517834,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-05-14T11:53:11.000Z","date":"2024-05-13","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0.49,"value":4900.0,"ownership":{"direct":true},"balance_after":1099865,"source":{"system":"sec-edgar","filing":"0001104659-24-060889","document":"tm2414376-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924060889/tm2414376-1_4seq1.xml","form_type":"4"}},{"id":1517833,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-05-14T11:53:11.000Z","date":"2024-05-11","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0.4665,"value":4665.0,"ownership":{"direct":true},"balance_after":1089865,"source":{"system":"sec-edgar","filing":"0001104659-24-060889","document":"tm2414376-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924060889/tm2414376-1_4seq1.xml","form_type":"4"}},{"id":1517832,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-05-14T11:53:11.000Z","date":"2024-05-10","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0.465,"value":9300.0,"ownership":{"direct":true},"balance_after":1079865,"source":{"system":"sec-edgar","filing":"0001104659-24-060889","document":"tm2414376-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924060889/tm2414376-1_4seq1.xml","form_type":"4"}},{"id":1525021,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-05-07T23:41:40.000Z","date":"2024-05-07","kind":"grant","planned":false,"acquired":true,"shares":66300,"price":0.3743,"value":24816.09,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.3738 to $0.3747, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":1059865,"source":{"system":"sec-edgar","filing":"0001104659-24-058218","document":"tm2413818-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924058218/tm2413818-1_4seq1.xml","form_type":"4"}},{"id":1525020,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-05-07T13:14:17.000Z","date":"2024-05-06","kind":"grant","planned":false,"acquired":true,"shares":135000,"price":0.3753,"value":50665.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.3498 to $0.399, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":993565,"source":{"system":"sec-edgar","filing":"0001104659-24-057784","document":"tm2413699-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924057784/tm2413699-1_4seq1.xml","form_type":"4"}},{"id":1535566,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-04-25T20:01:22.000Z","date":"2024-04-19","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0.5199,"value":7798.5,"ownership":{"direct":true},"balance_after":858565,"source":{"system":"sec-edgar","filing":"0001104659-24-051948","document":"tm2412707d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924051948/tm2412707d1_4seq1.xml","form_type":"4"}},{"id":1538566,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-04-19T10:05:13.000Z","date":"2024-04-18","kind":"grant","planned":false,"acquired":true,"shares":115072,"price":0.5255,"value":60470.336,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.4936 to $0.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":843565,"source":{"system":"sec-edgar","filing":"0001104659-24-049027","document":"tm2412256-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924049027/tm2412256-1_4seq1.xml","form_type":"4"}},{"id":1538565,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-04-19T10:05:13.000Z","date":"2024-04-17","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0.5457,"value":70941.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.5392 to $0.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":728493,"source":{"system":"sec-edgar","filing":"0001104659-24-049027","document":"tm2412256-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924049027/tm2412256-1_4seq1.xml","form_type":"4"}},{"id":1579174,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":18220,"kind":"person","name":"Lindborg Stacy","position":1,"cik":"0001813667","reported_name":"Lindborg Stacy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-14T00:57:42.000Z","date":"2024-03-11","kind":"grant","planned":false,"acquired":true,"shares":241935,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant of restricted stock awards (\"RSAs\") to the Reporting Person as reported herein was approved by the board of directors of the Issuer on March 11, 2024 (\"Grant Date\") as part of the Issuer's grant of equity awards in the ordinary course. The RSAs shall vest in equal yearly installments over the course of two (2) years, with vesting occurring on each of the first and second anniversary of the Grant Date."}],"balance_after":423435,"source":{"system":"sec-edgar","filing":"0001104659-24-034095","document":"tm248822-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924034095/tm248822-4_4seq1.xml","form_type":"4"}},{"id":1579173,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-14T00:56:54.000Z","date":"2024-03-11","kind":"grant","planned":false,"acquired":true,"shares":109426,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant of restricted stock awards (\"RSAs\") to the Reporting Person as reported herein was approved by the board of directors of the Issuer on March 11, 2024 (\"Grant Date\") as part of the Issuer's grant of equity awards in the ordinary course. The RSAs shall vest in equal yearly installments over the course of two (2) years, with vesting occurring on each of the first and second anniversary of the Grant Date."}],"balance_after":126969,"source":{"system":"sec-edgar","filing":"0001104659-24-034093","document":"tm248822-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924034093/tm248822-3_4seq1.xml","form_type":"4"}},{"id":1579172,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43250,"kind":"person","name":"Patlis Alla","position":1,"cik":"0001639227","reported_name":"Patlis Alla","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-03-14T00:55:55.000Z","date":"2024-03-11","kind":"grant","planned":false,"acquired":true,"shares":65246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant of restricted stock awards (\"RSAs\") to the Reporting Person as reported herein was approved by the board of directors of the Issuer on March 11, 2024 (\"Grant Date\") as part of the Issuer's grant of equity awards in the ordinary course. The RSAs shall vest in equal yearly installments over the course of two (2) years, with vesting occurring on each of the first and second anniversary of the Grant Date."}],"balance_after":65246,"source":{"system":"sec-edgar","filing":"0001104659-24-034092","document":"tm248822-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924034092/tm248822-2_4seq1.xml","form_type":"4"}},{"id":1579171,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-03-14T00:54:41.000Z","date":"2024-03-11","kind":"grant","planned":false,"acquired":true,"shares":305198,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant of restricted stock awards (\"RSAs\") to the Reporting Person as reported herein was approved by the board of directors of the Issuer on March 11, 2024 (\"Grant Date\") as part of the Issuer's grant of equity awards in the ordinary course. The RSAs shall vest in equal yearly installments over the course of two (2) years, with vesting occurring on each of the first and second anniversary of the Grant Date."}],"balance_after":598493,"source":{"system":"sec-edgar","filing":"0001104659-24-034091","document":"tm248822-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924034091/tm248822-1_4seq1.xml","form_type":"4"}},{"id":1789667,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":18220,"kind":"person","name":"Lindborg Stacy","position":1,"cik":"0001813667","reported_name":"Lindborg Stacy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-09-05T21:16:20.000Z","date":"2023-09-01","kind":"purchase","planned":false,"acquired":true,"shares":11500,"price":1.7741,"value":20402.15,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.74 to $1.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":181500,"source":{"system":"sec-edgar","filing":"0001104659-23-098326","document":"tm2325491-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923098326/tm2325491-1_4seq1.xml","form_type":"4"}},{"id":1814031,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":18220,"kind":"person","name":"Lindborg Stacy","position":1,"cik":"0001813667","reported_name":"Lindborg Stacy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-07T10:02:05.000Z","date":"2023-08-02","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of August 2, 2023, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date."}],"balance_after":170000,"source":{"system":"sec-edgar","filing":"0001104659-23-088000","document":"tm2322868-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923088000/tm2322868-1_4seq1.xml","form_type":"4"}},{"id":1815195,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-08-04T20:05:35.000Z","date":"2023-08-02","kind":"grant","planned":false,"acquired":true,"shares":31185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of July 26, 2023, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date."}],"balance_after":293295,"source":{"system":"sec-edgar","filing":"0001104659-23-087819","document":"tm2322868-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923087819/tm2322868-2_4seq1.xml","form_type":"4"}},{"id":1848088,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":28976,"kind":"person","name":"Naor Nir","position":1,"cik":"0001982278","reported_name":"Naor Nir","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-21T20:06:43.000Z","date":"2023-06-19","kind":"grant","planned":false,"acquired":true,"shares":11999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded on June 19, 2023 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on June 19, 2023 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director (and committee member, as applicable) of Brainstorm Cell Therapeutics Inc. on each vesting date."}],"balance_after":11999,"source":{"system":"sec-edgar","filing":"0001104659-23-073331","document":"tm2319343d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923073331/tm2319343d2_4.xml","form_type":"4"}},{"id":1910330,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":114050,"kind":"person","name":"Taylor Kirk","position":1,"cik":"0001975703","reported_name":"Taylor Kirk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-01T20:24:34.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option (the \"Option\"), awarded under the Plan, shall vest and become exercisable as to 25% of the underlying shares on May 1, 2024, and the remaining shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the grant date, provided that the Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date."}],"balance_after":80000,"derivative":{"exercise_price":2.99,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-23-054393","document":"tm2313994-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923054393/tm2313994-2_4seq1.xml","form_type":"4"}},{"id":1910329,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":114050,"kind":"person","name":"Taylor Kirk","position":1,"cik":"0001975703","reported_name":"Taylor Kirk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-05-01T20:24:34.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan (the \"Plan\"). The shares of restricted stock will vest in full on May 1, 2024, provided that the Reporting Person remains employed by Issuer from the date of grant through the vesting date."}],"balance_after":35000,"source":{"system":"sec-edgar","filing":"0001104659-23-054393","document":"tm2313994-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923054393/tm2313994-2_4seq1.xml","form_type":"4"}},{"id":1915040,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Co-CEO"}}],"security":"Common Stock","published_at":"2023-04-24T10:44:08.000Z","date":"2023-04-20","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares were fully vested upon grant."}],"balance_after":262110,"source":{"system":"sec-edgar","filing":"0001104659-23-048639","document":"tm2313513-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923048639/tm2313513-2_4seq1.xml","form_type":"4"}},{"id":1915039,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":18220,"kind":"person","name":"Lindborg Stacy","position":1,"cik":"0001813667","reported_name":"Lindborg Stacy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-24T10:42:36.000Z","date":"2023-04-20","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares were fully vested upon grant."}],"balance_after":135000,"source":{"system":"sec-edgar","filing":"0001104659-23-048632","document":"tm2313513-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923048632/tm2313513-1_4seq1.xml","form_type":"4"}},{"id":2068934,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":18220,"kind":"person","name":"Lindborg Stacy","position":1,"cik":"0001813667","reported_name":"Lindborg Stacy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-04T12:36:29.000Z","date":"2022-12-07","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of December 7, 2022, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001104659-23-000636","document":"tm231419-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923000636/tm231419-1_4seq1.xml","form_type":"4"}},{"id":2068905,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-04T12:35:25.000Z","date":"2022-09-18","kind":"grant","acquired":true,"shares":31185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of July 26, 2022, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date."}],"balance_after":187110,"source":{"system":"sec-edgar","filing":"0001104659-23-000634","document":"tm231419-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923000634/tm231419-2_4seq1.xml","form_type":"4"}},{"id":2300532,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":28337,"kind":"person","name":"FRENKEL JACOB A","position":1,"cik":"0001237418","reported_name":"FRENKEL JACOB A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-08T20:30:46.000Z","date":"2022-04-06","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Second Amended and Restated Director Compensation Plan, as amended, this option shall vest and become exercisable in 12 consecutive, equal monthly installments commencing on May 6, 2022 until fully vested and exercisable on the 12 month anniversary of April 6, 2022, provided that the Reporting Person remains a member of the Board of Directors of the Issuer on each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":0.75,"expiration_date":"2032-04-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-22-044247","document":"tm2212273-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465922044247/tm2212273-1_4seq1.xml","form_type":"4"}},{"id":2335883,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":129155,"kind":"person","name":"Kern Ralph Dr.","position":1,"cik":"0001699684","reported_name":"Kern Ralph Dr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-15T00:00:52.000Z","date":"2022-03-06","kind":"grant","acquired":true,"shares":35885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of March 6, 2022, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date."}],"balance_after":223310,"source":{"system":"sec-edgar","filing":"0001104659-22-033496","document":"tm228679-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465922033496/tm228679-1_4seq1.xml","form_type":"4"}},{"id":2414522,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":45750,"kind":"person","name":"Polverino Anthony J.","position":1,"cik":"0001729957","reported_name":"Polverino Anthony J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-03T21:33:53.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":3882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 1, 2022 until fully vested on the first anniversary of February 1, 2022, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date."}],"balance_after":25960,"source":{"system":"sec-edgar","filing":"0001104659-22-011390","document":"tm225365-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465922011390/tm225365-1_4seq1.xml","form_type":"4"}},{"id":2468049,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":132246,"kind":"person","name":"TAUB MALCOLM S","position":1,"cik":"0001305117","reported_name":"TAUB MALCOLM S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-17T22:04:15.000Z","date":"2021-12-15","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded in connection with the Company's 2021 Annual Meeting of Stockholders pursuant to the Company's Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested on the first anniversary of December 15, 2021."}],"balance_after":77332,"source":{"system":"sec-edgar","filing":"0001104659-21-151218","document":"tm2135659-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921151218/tm2135659-5_4seq1.xml","form_type":"4"}},{"id":2468048,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":45750,"kind":"person","name":"Polverino Anthony J.","position":1,"cik":"0001729957","reported_name":"Polverino Anthony J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-17T22:03:22.000Z","date":"2021-12-15","kind":"grant","acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded in connection with the Company's 2021 Annual Meeting of Stockholders pursuant to the Company's Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested on the first anniversary of December 15, 2021."}],"balance_after":22078,"source":{"system":"sec-edgar","filing":"0001104659-21-151215","document":"tm2135659-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921151215/tm2135659-4_4seq1.xml","form_type":"4"}},{"id":2468047,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-17T22:02:35.000Z","date":"2021-12-15","kind":"grant","acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded in connection with the Company's 2021 Annual Meeting of Stockholders pursuant to the Company's Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested on the first anniversary of December 15, 2021."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001104659-21-151214","document":"tm2135659-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921151214/tm2135659-3_4seq1.xml","form_type":"4"}},{"id":2468046,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-17T22:01:38.000Z","date":"2021-12-15","kind":"grant","acquired":true,"shares":13333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests and become exercisable in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested and exercisable on the 12 month anniversary of December 15, 2021."}],"balance_after":13333,"derivative":{"exercise_price":0.75,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":13333},"source":{"system":"sec-edgar","filing":"0001104659-21-151211","document":"tm2135659-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921151211/tm2135659-2_4seq1.xml","form_type":"4"}},{"id":2468045,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43248,"kind":"person","name":"ARBEL IRIT","position":1,"cik":"0001245607","reported_name":"ARBEL IRIT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-17T22:00:38.000Z","date":"2021-12-15","kind":"grant","acquired":true,"shares":25333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested and exercisable on the 12 month anniversary of December 15, 2021."}],"balance_after":25333,"derivative":{"exercise_price":0.75,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":25333},"source":{"system":"sec-edgar","filing":"0001104659-21-151209","document":"tm2135659-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921151209/tm2135659-1_4seq1.xml","form_type":"4"}},{"id":2477591,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":129155,"kind":"person","name":"Kern Ralph Dr.","position":1,"cik":"0001699684","reported_name":"Kern Ralph Dr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-11T01:05:07.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":35885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of March 6, 2021, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date."}],"balance_after":187425,"source":{"system":"sec-edgar","filing":"0001104659-21-148754","document":"tm2135032-9_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921148754/tm2135032-9_4.xml","form_type":"4"}},{"id":2477590,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-11T01:04:41.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":31185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of July 26, 2021, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date."}],"balance_after":155925,"source":{"system":"sec-edgar","filing":"0001104659-21-148753","document":"tm2135032-8_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921148753/tm2135032-8_4.xml","form_type":"4"}},{"id":2477589,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":132246,"kind":"person","name":"TAUB MALCOLM S","position":1,"cik":"0001305117","reported_name":"TAUB MALCOLM S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T01:04:05.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded effective November 11, 2020 in connection with the Company's 2020 Annual Meeting of Stockholders, pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested on the first anniversary of November 11, 2020, provided that the reporting person remained a director of Brainstorm Cell Therapeutics on each vesting date."}],"balance_after":65332,"source":{"system":"sec-edgar","filing":"0001104659-21-148752","document":"tm2135032-7_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921148752/tm2135032-7_4.xml","form_type":"4"}},{"id":2477588,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":45750,"kind":"person","name":"Polverino Anthony J.","position":1,"cik":"0001729957","reported_name":"Polverino Anthony J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T01:03:30.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares acquired are shares of restricted stock awarded in connection with the Company's 2020 Annual Meeting of Stockholders pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan . The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested on the first anniversary of November 11, 2020, provided that the reporting person remained a director of Brainstorm Cell Therapeutics on each vesting date."}],"balance_after":20078,"source":{"system":"sec-edgar","filing":"0001104659-21-148751","document":"tm2135032-6_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921148751/tm2135032-6_4.xml","form_type":"4"}},{"id":2477587,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":45750,"kind":"person","name":"Polverino Anthony J.","position":1,"cik":"0001729957","reported_name":"Polverino Anthony J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T01:03:30.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":2216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 1, 2021 until fully vested on the first anniversary of February 1, 2021, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date."}],"balance_after":18078,"source":{"system":"sec-edgar","filing":"0001104659-21-148751","document":"tm2135032-6_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921148751/tm2135032-6_4.xml","form_type":"4"}},{"id":2477586,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43248,"kind":"person","name":"ARBEL IRIT","position":1,"cik":"0001245607","reported_name":"ARBEL IRIT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-11T01:02:58.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":25333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the Company's 2020 Annual Meeting of Stockholders, pursuant to the Company's Second Amended and Restated Director Compensation Plan, as amended, option vested and became exercisable in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested and exercisable on the 12 month anniversary of November 11, 2020, provided that the Reporting Person remained a member of the Board of Directors of the Issuer on each vesting date."}],"balance_after":25333,"derivative":{"exercise_price":0.75,"expiration_date":"2031-12-10","underlying":"Common Stock","underlying_shares":25333},"source":{"system":"sec-edgar","filing":"0001104659-21-148750","document":"tm2135032-5_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921148750/tm2135032-5_4.xml","form_type":"4"}},{"id":2477585,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":28337,"kind":"person","name":"FRENKEL JACOB A","position":1,"cik":"0001237418","reported_name":"FRENKEL JACOB A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-11T01:02:28.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Second Amended and Restated Director Compensation Plan, as amended, option vested and became exercisable in 12 consecutive, equal monthly installments commencing on May 6, 2021 until fully vested and exercisable on the 12 month anniversary of April 6, 2021, provided that the Reporting Person remained a member of the Board of Directors of the Issuer on each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":0.75,"expiration_date":"2031-12-10","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-21-148749","document":"tm2135032-4_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921148749/tm2135032-4_4.xml","form_type":"4"}},{"id":2477583,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":132563,"kind":"person","name":"Abbhi Sankesh","position":1,"cik":"0001806887","reported_name":"Abbhi Sankesh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T01:02:02.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":6666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on the one month anniversary of April 6, 2021 until fully vested on the 12 month anniversary of April 6, 2021, provided that the Reporting Person remained a member of the Board of Directors of the Issuer on each vesting date."}],"balance_after":11323,"source":{"system":"sec-edgar","filing":"0001104659-21-148748","document":"tm2135032-3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921148748/tm2135032-3_4.xml","form_type":"4"}},{"id":2477584,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-11T01:01:33.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":13333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the Company's 2020 Annual Meeting of Stockholders, pursuant to the Company's Second Amended and Restated Director Compensation Plan, as amended, option vested and became exercisable in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested and exercisable on the 12 month anniversary of November 11, 2020, provided that the Reporting Person remained a member of the Board of Directors of the Issuer on each vesting date."}],"balance_after":13333,"derivative":{"exercise_price":0.75,"expiration_date":"2031-12-10","underlying":"Common Stock","underlying_shares":13333},"source":{"system":"sec-edgar","filing":"0001104659-21-148747","document":"tm2135032-2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921148747/tm2135032-2_4.xml","form_type":"4"}},{"id":2477582,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T01:00:45.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded in connection with the Company's 2020 Annual Meeting of Stockholders pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested on the first anniversary of November 11, 2020, provided that the reporting person remained a director (and committee member, as applicable) of Brainstorm Cell Therapeutics on each vesting date."}],"balance_after":4000,"source":{"system":"sec-edgar","filing":"0001104659-21-148745","document":"tm2135032-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921148745/tm2135032-1_4.xml","form_type":"4"}},{"id":2927902,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":29685,"kind":"person","name":"Shah Preetam","position":1,"cik":"0001787403","reported_name":"Shah Preetam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-01T02:20:04.000Z","date":"2020-12-30","kind":"tax_withholding","acquired":false,"shares":25000,"price":4.64,"value":116000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of common stock withheld by the issuer to satisfy tax withholding obligations in connection with the vesting of a previously reported restricted stock award."}],"balance_after":11600,"source":{"system":"sec-edgar","filing":"0001104659-20-141128","document":"tm2039739-1d4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920141128/tm2039739-1d4.xml","form_type":"4"}},{"id":2973440,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":18220,"kind":"person","name":"Lindborg Stacy","position":1,"cik":"0001813667","reported_name":"Lindborg Stacy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head Global Clin Research"}}],"security":"Call Option (right to buy)","published_at":"2020-11-19T23:00:51.000Z","date":"2020-11-17","kind":"purchase","acquired":true,"shares":200,"price":11000,"value":2200000.0,"ownership":{"direct":true},"balance_after":200,"derivative":{"exercise_price":10,"exercise_date":"2020-11-17","expiration_date":"2021-05-21","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-20-127446","document":"tm2036490-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920127446/tm2036490-1_4.xml","form_type":"4"}},{"id":3034559,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":146710,"kind":"person","name":"Waclawski Anthony","position":1,"cik":"0001823486","reported_name":"Waclawski Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-10T20:07:46.000Z","date":"2020-09-08","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These shares shall vest in full on the one year anniversary of the date of grant."}],"balance_after":80000,"derivative":{"exercise_price":12.58,"expiration_date":"2030-09-08","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-20-103943","document":"tm2030582d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920103943/tm2030582d1_4.xml","form_type":"4"}},{"id":3034558,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":146710,"kind":"person","name":"Waclawski Anthony","position":1,"cik":"0001823486","reported_name":"Waclawski Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-09-10T20:07:46.000Z","date":"2020-09-08","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded effective on September 8, 2020 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest in full on July 1, 2021, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date."}],"balance_after":35000,"source":{"system":"sec-edgar","filing":"0001104659-20-103943","document":"tm2030582d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920103943/tm2030582d1_4.xml","form_type":"4"}},{"id":3072671,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43252,"kind":"person","name":"Lebovits Chaim","position":1,"cik":"0001406302","reported_name":"Lebovits Chaim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-07-31T21:10:22.000Z","date":"2020-07-26","kind":"grant","acquired":true,"shares":31185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded on July 26, 2020 under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date."}],"balance_after":124740,"source":{"system":"sec-edgar","filing":"0001104659-20-089158","document":"tm2025773d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920089158/tm2025773d1_4.xml","form_type":"4"}},{"id":3081912,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":132563,"kind":"person","name":"Abbhi Sankesh","position":1,"cik":"0001806887","reported_name":"Abbhi Sankesh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-16T21:15:28.000Z","date":"2020-07-15","kind":"purchase","acquired":true,"shares":46779,"price":12.99,"value":607659.21,"ownership":{"direct":false,"nature":"Abbhi Investments, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.82 to $13.14, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Abbhi Investments, LLC is the record owner of these securities. Mr. Sankesh Abbhi is the manager of Abbhi Investments, LLC and maintains sole voting and investment power with respect to common stock and warrants held by Abbhi Investments, LLC."}],"balance_after":2164530,"source":{"system":"sec-edgar","filing":"0001104659-20-084127","document":"tm2024951d1_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920084127/tm2024951d1_form4.xml","form_type":"4"}},{"id":3081903,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":147788,"kind":"person","name":"Setboun David","position":1,"cik":"0001807545","reported_name":"Setboun David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and COO"}}],"security":"Common Stock","published_at":"2020-07-16T21:10:28.000Z","date":"2020-07-16","kind":"purchase","acquired":true,"shares":5000,"price":12.948,"value":64740.0,"ownership":{"direct":true},"balance_after":55000,"source":{"system":"sec-edgar","filing":"0001104659-20-084123","document":"tm2024951-2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920084123/tm2024951-2_4.xml","form_type":"4"}},{"id":3081908,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":147789,"kind":"organization","name":"ACC International Holdings Ltd.","position":1,"cik":"0001521843","reported_name":"ACC International Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Common Stock","published_at":"2020-07-16T21:05:22.000Z","date":"2020-07-16","kind":"sale","acquired":false,"shares":7823,"price":13.4668,"value":105350.7764,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $13.46 to $13.4684, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":67053,"source":{"system":"sec-edgar","filing":"0001104659-20-084119","document":"tm2024939d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920084119/tm2024939d1_4.xml","form_type":"4"}},{"id":3081907,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":147789,"kind":"organization","name":"ACC International Holdings Ltd.","position":1,"cik":"0001521843","reported_name":"ACC International Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Common Stock","published_at":"2020-07-16T21:05:22.000Z","date":"2020-07-15","kind":"sale","acquired":false,"shares":18430,"price":13.1153,"value":241714.979,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.1 to $13.15, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":74876,"source":{"system":"sec-edgar","filing":"0001104659-20-084119","document":"tm2024939d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920084119/tm2024939d1_4.xml","form_type":"4"}},{"id":3081906,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":147789,"kind":"organization","name":"ACC International Holdings Ltd.","position":1,"cik":"0001521843","reported_name":"ACC International Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Common Stock","published_at":"2020-07-16T21:05:22.000Z","date":"2020-07-13","kind":"sale","acquired":false,"shares":40000,"price":13.5238,"value":540952.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.338 to $13.61, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":93306,"source":{"system":"sec-edgar","filing":"0001104659-20-084119","document":"tm2024939d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920084119/tm2024939d1_4.xml","form_type":"4"}},{"id":3081905,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":147789,"kind":"organization","name":"ACC International Holdings Ltd.","position":1,"cik":"0001521843","reported_name":"ACC International Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Common Stock","published_at":"2020-07-16T21:05:22.000Z","date":"2020-07-10","kind":"sale","acquired":false,"shares":2000,"price":13.35,"value":26700.0,"ownership":{"direct":true},"balance_after":133306,"source":{"system":"sec-edgar","filing":"0001104659-20-084119","document":"tm2024939d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920084119/tm2024939d1_4.xml","form_type":"4"}},{"id":3081904,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":147789,"kind":"organization","name":"ACC International Holdings Ltd.","position":1,"cik":"0001521843","reported_name":"ACC International Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Common Stock","published_at":"2020-07-16T21:05:22.000Z","date":"2020-07-09","kind":"sale","acquired":false,"shares":3500,"price":13.1253,"value":45938.55,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.0816 to $13.1581, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":135306,"source":{"system":"sec-edgar","filing":"0001104659-20-084119","document":"tm2024939d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920084119/tm2024939d1_4.xml","form_type":"4"}},{"id":3099167,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-06-26T21:00:45.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":17543,"source":{"system":"sec-edgar","filing":"0001104659-20-077512","document":"tm2023245d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920077512/tm2023245d1_4.xml","form_type":"4"}},{"id":3129305,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":18220,"kind":"person","name":"Lindborg Stacy","position":1,"cik":"0001813667","reported_name":"Lindborg Stacy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head Global Clin Research"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-01T21:32:04.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option, awarded on June 1, 2020 under the Issuer's 2014 Stock Incentive Plan, shall vest and become exercisable as to 50,000 of the underlying shares on February 28, 2021 (\"First Vesting Date\"), and the remaining 50,000 shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter until fully vested and exercisable on the second anniversary of the First Vesting Date, provided Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":7.67,"exercise_date":"2021-02-28","expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-20-068501","document":"tm2021119-2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920068501/tm2021119-2_4.xml","form_type":"4"}},{"id":3129304,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":18220,"kind":"person","name":"Lindborg Stacy","position":1,"cik":"0001813667","reported_name":"Lindborg Stacy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head Global Clin Research"}}],"security":"Common Stock","published_at":"2020-06-01T21:32:04.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded on June 1, 2020 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 100% of the award on December 31, 2020, provided that the Reporting Person remains continuously employed by Issuer from the date of grant through the vesting date."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001104659-20-068501","document":"tm2021119-2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920068501/tm2021119-2_4.xml","form_type":"4"}},{"id":3180864,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":147788,"kind":"person","name":"Setboun David","position":1,"cik":"0001807545","reported_name":"Setboun David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and COO"}}],"security":"Common Stock","published_at":"2020-04-07T22:16:22.000Z","date":"2020-04-07","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded on April 7, 2020 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 100% of the award on the one year anniversary of the date of grant, provided that the Reporting Person remains continuously employed by Issuer from the date of grant through the vesting date."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001104659-20-044272","document":"tm2014134d6_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920044272/tm2014134d6_4.xml","form_type":"4"}}],"next_cursor":"2020-04-07T22:16:22.000000Z,3180864"}